The Ramco Cements Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 19, 2025, 10:46 pm

Competitors of The Ramco Cements Ltd

All Competitor Stocks of The Ramco Cements Ltd

Quarterly Result

Last Updated: August 20, 2025, 2:20 am

Below is a detailed analysis of the quarterly data for The Ramco Cements Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 2,070.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,392.00 Cr. (Mar 2025) to 2,070.00 Cr., marking a decrease of 322.00 Cr..
• For Expenses, as of Jun 2025, the value is 1,672.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 2,071.00 Cr. (Mar 2025) to 1,672.00 Cr., marking a decrease of 399.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 398.00 Cr.. The value appears strong and on an upward trend. It has increased from 321.00 Cr. (Mar 2025) to 398.00 Cr., marking an increase of 77.00 Cr..
• For OPM %, as of Jun 2025, the value is 19.00%. The value appears strong and on an upward trend. It has increased from 13.00% (Mar 2025) to 19.00%, marking an increase of 6.00%.
• For Other Income, as of Jun 2025, the value is 6.00 Cr.. The value appears to be declining and may need further review. It has decreased from 24.00 Cr. (Mar 2025) to 6.00 Cr., marking a decrease of 18.00 Cr..
• For Interest, as of Jun 2025, the value is 105.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 113.00 Cr. (Mar 2025) to 105.00 Cr., marking a decrease of 8.00 Cr..
• For Depreciation, as of Jun 2025, the value is 183.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 182.00 Cr. (Mar 2025) to 183.00 Cr., marking an increase of 1.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 116.00 Cr.. The value appears strong and on an upward trend. It has increased from 49.00 Cr. (Mar 2025) to 116.00 Cr., marking an increase of 67.00 Cr..
• For Tax %, as of Jun 2025, the value is 26.00%. The value appears to be improving (decreasing) as expected. It has decreased from 37.00% (Mar 2025) to 26.00%, marking a decrease of 11.00%.
• For Net Profit, as of Jun 2025, the value is 86.00 Cr.. The value appears strong and on an upward trend. It has increased from 31.00 Cr. (Mar 2025) to 86.00 Cr., marking an increase of 55.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 3.64. The value appears strong and on an upward trend. It has increased from 1.31 (Mar 2025) to 3.64, marking an increase of 2.33.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: November 15, 2025, 4:18 am

Growth

Last Updated: September 5, 2025, 1:46 pm

Balance Sheet

Last Updated: November 9, 2025, 3:06 pm

Below is a detailed analysis of the balance sheet data for The Ramco Cements Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

• For Equity Capital, as of Sep 2025, the value is 24.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 24.00 Cr..
• For Reserves, as of Sep 2025, the value is 7,588.00 Cr.. The value appears strong and on an upward trend. It has increased from 7,470.00 Cr. (Mar 2025) to 7,588.00 Cr., marking an increase of 118.00 Cr..
• For Borrowings, as of Sep 2025, the value is 4,699.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 4,675.00 Cr. (Mar 2025) to 4,699.00 Cr., marking an increase of 24.00 Cr..
• For Other Liabilities, as of Sep 2025, the value is 4,310.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4,206.00 Cr. (Mar 2025) to 4,310.00 Cr., marking an increase of 104.00 Cr..
• For Total Liabilities, as of Sep 2025, the value is 16,620.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 16,374.00 Cr. (Mar 2025) to 16,620.00 Cr., marking an increase of 246.00 Cr..
• For Fixed Assets, as of Sep 2025, the value is 12,858.00 Cr.. The value appears strong and on an upward trend. It has increased from 12,338.00 Cr. (Mar 2025) to 12,858.00 Cr., marking an increase of 520.00 Cr..
• For CWIP, as of Sep 2025, the value is 1,067.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,386.00 Cr. (Mar 2025) to 1,067.00 Cr., marking a decrease of 319.00 Cr..
• For Investments, as of Sep 2025, the value is 104.00 Cr.. The value appears to be declining and may need further review. It has decreased from 135.00 Cr. (Mar 2025) to 104.00 Cr., marking a decrease of 31.00 Cr..
• For Other Assets, as of Sep 2025, the value is 2,591.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,515.00 Cr. (Mar 2025) to 2,591.00 Cr., marking an increase of 76.00 Cr..
• For Total Assets, as of Sep 2025, the value is 16,620.00 Cr.. The value appears strong and on an upward trend. It has increased from 16,374.00 Cr. (Mar 2025) to 16,620.00 Cr., marking an increase of 246.00 Cr..

Notably, the Reserves (7,588.00 Cr.) exceed the Borrowings (4,699.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for The Ramco Cements Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 11.53. This value is within the healthy range. It has decreased from 15.77 (Mar 24) to 11.53, marking a decrease of 4.24.
• For Diluted EPS (Rs.), as of Mar 25, the value is 11.53. This value is within the healthy range. It has decreased from 15.77 (Mar 24) to 11.53, marking a decrease of 4.24.
• For Cash EPS (Rs.), as of Mar 25, the value is 40.76. This value is within the healthy range. It has decreased from 44.01 (Mar 24) to 40.76, marking a decrease of 3.25.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 314.92. It has increased from 306.45 (Mar 24) to 314.92, marking an increase of 8.47.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 314.92. It has increased from 306.45 (Mar 24) to 314.92, marking an increase of 8.47.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 360.49. It has decreased from 396.80 (Mar 24) to 360.49, marking a decrease of 36.31.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 53.90. This value is within the healthy range. It has decreased from 67.86 (Mar 24) to 53.90, marking a decrease of 13.96.
• For PBIT / Share (Rs.), as of Mar 25, the value is 24.49. This value is within the healthy range. It has decreased from 40.51 (Mar 24) to 24.49, marking a decrease of 16.02.
• For PBT / Share (Rs.), as of Mar 25, the value is 13.51. This value is within the healthy range. It has decreased from 22.92 (Mar 24) to 13.51, marking a decrease of 9.41.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 11.35. This value is within the healthy range. It has decreased from 16.65 (Mar 24) to 11.35, marking a decrease of 5.30.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 11.54. This value is within the healthy range. It has decreased from 15.23 (Mar 24) to 11.54, marking a decrease of 3.69.
• For PBDIT Margin (%), as of Mar 25, the value is 14.95. This value is within the healthy range. It has decreased from 17.10 (Mar 24) to 14.95, marking a decrease of 2.15.
• For PBIT Margin (%), as of Mar 25, the value is 6.79. This value is below the healthy minimum of 10. It has decreased from 10.20 (Mar 24) to 6.79, marking a decrease of 3.41.
• For PBT Margin (%), as of Mar 25, the value is 3.74. This value is below the healthy minimum of 10. It has decreased from 5.77 (Mar 24) to 3.74, marking a decrease of 2.03.
• For Net Profit Margin (%), as of Mar 25, the value is 3.14. This value is below the healthy minimum of 5. It has decreased from 4.19 (Mar 24) to 3.14, marking a decrease of 1.05.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 3.20. This value is below the healthy minimum of 8. It has decreased from 3.83 (Mar 24) to 3.20, marking a decrease of 0.63.
• For Return on Networth / Equity (%), as of Mar 25, the value is 3.66. This value is below the healthy minimum of 15. It has decreased from 4.97 (Mar 24) to 3.66, marking a decrease of 1.31.
• For Return on Capital Employeed (%), as of Mar 25, the value is 4.81. This value is below the healthy minimum of 10. It has decreased from 7.78 (Mar 24) to 4.81, marking a decrease of 2.97.
• For Return On Assets (%), as of Mar 25, the value is 1.66. This value is below the healthy minimum of 5. It has decreased from 2.21 (Mar 24) to 1.66, marking a decrease of 0.55.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.45. This value is within the healthy range. It has decreased from 0.54 (Mar 24) to 0.45, marking a decrease of 0.09.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.62. This value is within the healthy range. It has decreased from 0.67 (Mar 24) to 0.62, marking a decrease of 0.05.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.52. It has decreased from 0.60 (Mar 24) to 0.52, marking a decrease of 0.08.
• For Current Ratio (X), as of Mar 25, the value is 0.51. This value is below the healthy minimum of 1.5. It has decreased from 0.56 (Mar 24) to 0.51, marking a decrease of 0.05.
• For Quick Ratio (X), as of Mar 25, the value is 0.28. This value is below the healthy minimum of 1. It has decreased from 0.31 (Mar 24) to 0.28, marking a decrease of 0.03.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 8.52. This value exceeds the healthy maximum of 8. It has increased from 1.87 (Mar 24) to 8.52, marking an increase of 6.65.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 21.68. This value is within the healthy range. It has increased from 13.14 (Mar 24) to 21.68, marking an increase of 8.54.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 6.11. This value is below the healthy minimum of 20. It has increased from 4.70 (Mar 24) to 6.11, marking an increase of 1.41.
• For Earning Retention Ratio (%), as of Mar 25, the value is 78.32. This value exceeds the healthy maximum of 70. It has decreased from 86.86 (Mar 24) to 78.32, marking a decrease of 8.54.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 93.89. This value exceeds the healthy maximum of 70. It has decreased from 95.30 (Mar 24) to 93.89, marking a decrease of 1.41.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 2.78. This value is below the healthy minimum of 3. It has decreased from 3.86 (Mar 24) to 2.78, marking a decrease of 1.08.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.15. This value is below the healthy minimum of 3. It has decreased from 1.95 (Mar 24) to 1.15, marking a decrease of 0.80.
• For Enterprise Value (Cr.), as of Mar 25, the value is 25,669.09. It has increased from 23,941.52 (Mar 24) to 25,669.09, marking an increase of 1,727.57.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.01. This value exceeds the healthy maximum of 3. It has increased from 2.55 (Mar 24) to 3.01, marking an increase of 0.46.
• For EV / EBITDA (X), as of Mar 25, the value is 20.15. This value exceeds the healthy maximum of 15. It has increased from 14.93 (Mar 24) to 20.15, marking an increase of 5.22.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.49. This value is within the healthy range. It has increased from 2.04 (Mar 24) to 2.49, marking an increase of 0.45.
• For Retention Ratios (%), as of Mar 25, the value is 78.31. This value exceeds the healthy maximum of 70. It has decreased from 86.85 (Mar 24) to 78.31, marking a decrease of 8.54.
• For Price / BV (X), as of Mar 25, the value is 2.85. This value is within the healthy range. It has increased from 2.65 (Mar 24) to 2.85, marking an increase of 0.20.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.49. This value is within the healthy range. It has increased from 2.04 (Mar 24) to 2.49, marking an increase of 0.45.
• For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness